Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes

This publication has 26 references indexed in Scilit:

• Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1
  Genome Medicine, 2013
• The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy
  Clinical Pharmacology & Therapeutics, 2012
• Asthma phenotypes: the evolution from clinical to molecular approaches
  Nature Medicine, 2012
• Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin
  The Pharmacogenomics Journal, 2011
• Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go-DARTS Study
  Clinical Pharmacology & Therapeutics, 2010
• Impact of OATP transporters on pharmacokinetics
  British Journal of Pharmacology, 2009
• The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects
  JACC, 2009
• SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
  New England Journal of Medicine, 2008
• Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin
  Clinical Pharmacokinetics, 2008
• SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
  Pharmacogenetics and Genomics, 2006